{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T05:05:03Z","timestamp":1780031103116,"version":"3.53.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Age-related macular degeneration is a chronic and progressive disease that typically develops after the age of 50. Characterized by visual distortions, image blurring, and gradual central vision loss, age-related macular degeneration significantly impairs patients\u2019 ability to perform everyday activities and contributes to a marked reduction in quality of life. The gold standard treatment for the neovascular form of this condition consists of intravitreal injections. This therapy offers patients the possibility of improved vision-related quality of life by slowing disease progression and partially restoring visual function to levels approximating those prior to the onset of the condition. The aim of this study was to examine vision-related quality of life in individuals with neovascular age-related macular degeneration prior to treatment and following a course of seven intravitreal injections. The study also aimed to analyze its association with visual acuity, contrast sensitivity, and the occurrence and severity of metamorphopsia and central scotoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This survey-based study was carried out using the author\u2019s questionnaire and a standardized research tool\u2014the Polish version of National Eye Institute Visual Functioning Questionnaire. It also involved the analysis of the patients\u2019 medical records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study group consisted of 121 patients (121 eyes), comprising 60 women and 61 men, aged between 51 and 90 years. Following a course of intravitreal injections, a statistically significant improvement in vision-related quality of life, as measured by the Visual Functioning Questionnaire, was observed. The analysis also demonstrated an association between quality of life and visual function parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vision-related quality of life in patients with neovascular age-related macular degeneration was low at baseline and showed a modest improvement following initiation of intravitreal anti-VEGF therapy over the follow-up period. Across time points, better visual acuity, higher contrast sensitivity, and fewer visual disturbances on the Amsler grid were associated with higher vision-related quality of life scores. This study highlights the potential psychosocial benefits of intravitreal therapy in nAMD and may help support patients in initiating treatment or in maintaining adherence to continuing therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1731481","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:49:01Z","timestamp":1780030141000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality of life in patients with neovascular age-related macular degeneration before and after intravitreal therapy: a longitudinal observational study"],"prefix":"10.3389","volume":"13","author":[{"given":"Marta","family":"Nowak","sequence":"first","affiliation":[{"name":"Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin","place":["Szczecin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cybulska","sequence":"additional","affiliation":[{"name":"Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin","place":["Szczecin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Derezi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin","place":["Szczecin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"El\u017cbieta","family":"Grochans","sequence":"additional","affiliation":[{"name":"Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin","place":["Szczecin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz","family":"Panczyk","sequence":"additional","affiliation":[{"name":"Department of Education and Research in Health Sciences, Faculty of Health Sciences, Medical University of Warsaw","place":["Warsaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"K\u0119cka","sequence":"additional","affiliation":[{"name":"Department of Primary Health Care, Faculty of Health Sciences, Pomeranian Medical University in Szczecin","place":["Szczecin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamila","family":"Rachubi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Nursing, Faculty of Health Sciences, Pomeranian Medical University in Szczecin","place":["Szczecin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","article-title":"EYE-RISK consortium; European eye epidemiology (E3) consortium. Prevalence of age-related macular degeneration in Europe: the past and the future.","volume":"12","author":"Colijn","year":"2017","journal-title":"Ophthalmology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/B978-0-12-821377-3.00014-3","article-title":"Illusions, hallucinations, and visual snow.","volume":"178","author":"Fraser","year":"2021","journal-title":"Handb Clin Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-k","article-title":"The World health organization quality of life assessment (WHOQOL): position paper from the Word heath organization.","volume":"41","year":"1995","journal-title":"Soc Sci Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"622","DOI":"10.7326\/0003-4819-118-8-199304150-00009","article-title":"Measuring health-related quality of life.","volume":"118","author":"Guyatt","year":"1993","journal-title":"Ann Intern Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s40123-022-00631-7","article-title":"The patient voice in neovascular age-related macular degeneration: findings from a qualitative study.","volume":"1","author":"Talks","year":"2023","journal-title":"Ophthalmol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ajo.2010.05.030","article-title":"Impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the study of Osteoporotic fractures.","volume":"5","author":"Coleman","year":"2010","journal-title":"Am J Ophthalmol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1477-7525-4-97","article-title":"Quality of life in age-related macular degeneration: a review of the literature.","volume":"4","author":"Mitchell","year":"2006","journal-title":"Health Qual Life Outcomes."},{"key":"B9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/01.icu.0000193079.55240.18","article-title":"The burden of age-related macular degeneration: a value-based analysis.","volume":"3","author":"Brown","year":"2006","journal-title":"Curr Opin Ophthalmol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae.","volume":"1","author":"Flaxel","year":"2020","journal-title":"Ophthalmology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"CD005139","DOI":"10.1002\/14651858.CD005139.pub4","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.","volume":"3","author":"Solomon","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","article-title":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration: a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems.","volume":"1","author":"Finger","year":"2020","journal-title":"BMC Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1111\/aos.15201","article-title":"The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden.","volume":"1","author":"Gale","year":"2023","journal-title":"Acta Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"National eye institute visual function questionnaire field test investigators. Development of the 25-item national eye institute visual function questionnaire.","volume":"7","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40942-021-00290-z","article-title":"The effects of age-related macular degeneration on quality of life in a Brazilian population.","volume":"1","author":"Roque","year":"2021","journal-title":"Int J Retina Vitreous."},{"key":"B16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.3129\/i07-153","article-title":"Burden of illness of neovascular age-related macular degeneration in Canada.","volume":"6","author":"Cruess","year":"2007","journal-title":"Can J Ophthalmol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s00347-008-1797-9","article-title":"Neovascular age-related macular degeneration in Germany: encroachment on the quality of life and the financial implications.","volume":"3","author":"Pauleikhoff","year":"2009","journal-title":"Ophthalmologe."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2333721418801601","DOI":"10.1177\/2333721418801601","article-title":"The impact of age-related macular degeneration on quality of life and its association with demographic data: results from the NEI VFQ-25 questionnaire in a Norwegian population.","volume":"4","author":"Schippert","year":"2018","journal-title":"Gerontol Geriatr Med."},{"key":"B19","first-page":"A4290","article-title":"Danish version of the visual function questionnaire-25 and its use in age-related macular degeneration.","volume":"6","author":"S\u00f8rensen","year":"2011","journal-title":"Dan Med Bull."},{"key":"B20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/medicina48020015","article-title":"Quality of life in patients with age-related macular degeneration.","volume":"2","author":"\u0160iaudvytyt\u0117","year":"2012","journal-title":"Medicina."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e2022299","DOI":"10.23750\/abm.v93i6.13580","article-title":"Assessing the quality of life in age-related macular degeneration patients: a cross-sectional study in Kazakhstan.","volume":"6","author":"Ismayilova","year":"2022","journal-title":"Acta Biomed."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2147\/OPTH.S45248","article-title":"Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice.","volume":"7","author":"Yuzawa","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"602","DOI":"10.3390\/medicina58050602","article-title":"Chinese version of the vision-related quality of life (NEI-VFQ-25) among patients with various ocular disorders: a pilot study.","volume":"5","author":"Lee","year":"2022","journal-title":"Medicina."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration.","volume":"24","author":"Jager","year":"2008","journal-title":"N Engl J Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.2147\/OPTH.S68293","article-title":"Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life.","volume":"8","author":"Inoue","year":"2014","journal-title":"Clin Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10384-019-00687-2","article-title":"Vision-related quality of life in Japanese patients with wet age-related macular degeneration treated with intravitreal aflibercept in a real-world setting.","volume":"6","author":"Gomi","year":"2019","journal-title":"Jpn J Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.2147\/OPTH.S130182","article-title":"No improvement in injection frequency or in visual outcome over time in two cohorts of patients from the same Swedish county treated for wet age-related macular degeneration.","volume":"11","author":"Schroeder","year":"2017","journal-title":"Clin Ophthalmol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/OPTH.S41585","article-title":"Three-year follow-up of visual outcome and quality of life in patients with age-related macular degeneration.","volume":"7","author":"Rung","year":"2013","journal-title":"Clin Ophthalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e91004","DOI":"10.7759\/cureus.91004","article-title":"Quality of life and treatment satisfaction in patients receiving intravitreal injection therapy for neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a cross-sectional study.","volume":"8","author":"Flindris","year":"2025","journal-title":"Cureus."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.3390\/ijerph20042879","article-title":"Life quality in patients with impaired visual acuity undergoing intravitreal medication applications.","volume":"4","author":"Kola\u010dko","year":"2023","journal-title":"Int J Environ Res Public Health."},{"key":"B31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000433448","article-title":"Quality of life in patients suffering from active exudative age-related macular degeneration: the EQUADE study.","volume":"3","author":"Matamoros","year":"2015","journal-title":"Ophthalmologica."},{"key":"B32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jcjo.2017.08.006","article-title":"Metamorphopsia and vision-related quality of life among patients with age-related macular degeneration.","volume":"2","author":"Xu","year":"2018","journal-title":"Can J Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12886-020-01561-3","article-title":"Predictors of health-related quality of life in Chinese patients receiving treatment for neovascular age-related macular degeneration: a prospective longitudinal study.","volume":"20","author":"Bian","year":"2020","journal-title":"BMC Ophthalmol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1055\/s-0041-111835","article-title":"Langzeitergebnisse der intravitrealen anti-VEGF-Injektionstherapie bei feuchter altersabh\u00e4ngiger Makuladegeneration: eine Meta-Analyse [Long-term results of intravitreal anti-VEGF injections in wet AMD: a meta-analysis].","volume":"4","author":"Gerding","year":"2016","journal-title":"Klin Monbl Augenheilkd."},{"key":"B35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ph16070927","article-title":"Visual outcomes of anti-VEGF treatment on neovascular age-related macular degeneration: a real-world population-based cohort study.","volume":"7","author":"Korva-Gurung","year":"2023","journal-title":"Pharmaceuticals."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1731481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:49:15Z","timestamp":1780030155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1731481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":35,"alternative-id":["10.3389\/fmed.2026.1731481"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1731481","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1731481"}}